51 results about "Akt signalling" patented technology

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.

The invention discloses a copper ion-kaempferol nano-composite and application thereof in treatment of inflammatory bowel disease, the obtained nano-composite has very strong stability and active oxygen scavenging ability, and has excellent oxidation resistance and anti-inflammatory ability, and the specific performance is as follows: the surface is negatively charged, and the nano-composite can specifically target the diseased region of intestinal inflammation, so that the copper ion-kaempferol nano-composite can be applied to treatment of inflammatory bowel disease. The intestinal mucosal barrier injury is effectively repaired, the imbalance state of intestinal flora is adjusted, and the intestinal inflammation microenvironment is remarkably improved; the antioxidant and anti-inflammatory capacities of cells can be enhanced by regulating and controlling a PI3K-Akt signal channel and a nuclear factor kappa B (NF-kappa B) signal channel; the compound shows an excellent treatment effect in mouse models of typical inflammatory bowel diseases such as ulcerative colitis and Crohn's disease and related complications of bowel diseases. The invention provides a new way for constructing a multi-target and multi-layer treatment platform for the inflammatory bowel disease of a natural product.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

This invention discloses butylphthalide nanoparticles, comprising: a layered double hydroxide and butylphthalide, wherein the butylphthalide is loaded onto the layered double hydroxide. This invention also discloses a method for preparing the above-mentioned butylphthalide nanoparticles, comprising the following steps: mixing the layered double hydroxide, butylphthalide, and water, adsorbing, separating the solid and liquid phases, and drying to obtain butylphthalide nanoparticles. This invention further discloses the application of the above-mentioned butylphthalide nanoparticles in the preparation of drugs for treating acute renal ischemia-reperfusion injury. This invention also discloses a drug for treating acute renal ischemia-reperfusion injury, comprising: the above-mentioned butylphthalide nanoparticles and pharmaceutically acceptable excipients. The butylphthalide nanoparticles of this invention have high drug loading capacity, good stability, and can target and activate the PI3K-AKT signaling pathway, effectively inhibit HK-2 cell apoptosis and oxidative stress, restore mitochondrial function, and improve renal ischemia-reperfusion injury.

The invention belongs to the technical field of biological medicine, and provides a human umbilical cord mesenchymal stem cell preparation and application thereof, the preparation comprises human umbilical cord mesenchymal stem cells, ginsenoside Rg3 and a medicinal carrier; the medicinal carrier is a phosphate buffer solution; according to the application, 1 * 10 < 6 > HUCMSCs pretreated by Rg3 are subjected to caudal vein injection on a T2DM mouse model induced by high fat diet combined with STZ, the curative effect and mechanism are verified by combining OGTT, IPITT, serum biochemical detection, HE / PAS tissue staining, q-PCR and other technologies, and finally the purposes of improving glycometabolism of the T2DM mouse, repairing liver / kidney / pancreas target organ injuries, protecting pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions and the like are achieved. And a theoretical basis is provided for accurate intervention of T2DM by activating an IGF-1R / PI3K-AKT signal channel and regulating and controlling the expression of a glycometabolism-related gene.

The present application relates to the technical field of biological medicine, and particularly relates to a composition for protecting cochlear spiral ganglion neurons and application thereof. The composition comprises Panax notoginseng saponins (PNS) and Polygonatum sibiricum polysaccharide (PSP). Research shows that the composition can significantly improve the survival rate of neurons, promote neurite growth, reduce the level of reactive oxygen species, inhibit cell apoptosis, and promote autophagy by regulating the PI3K / AKT signaling pathway, thereby effectively resisting ototoxicity damage induced by aminoglycoside antibiotics. The present application further provides the use of the composition in the preparation of a drug for preventing or treating sensorineural hearing loss.

The invention relates to the technical field of immunology and biomedicine, in particular to application of CD23 as a target spot to preparation of a medicine for treating IL-17 mediated diseases. By enhancing the expression or function of CD23, an IL-7R alpha-mediated mTORC2-AKT signal channel is activated, the expression of Bcl-2 is promoted, and the apoptosis of NKT17 cells is inhibited, so that the steady state and function of the NKT17 cells are maintained. Experimental results show that the deletion of CD23 causes the reduction of NKT17 cells, the expression of p-AKT (Ser473) and Bcl-2 is reduced, and the signal activity can be recovered by the supplementation of exogenous IL-7. The dependency of the signal path is further verified by using an mTORC2 inhibitor. An airway hyperreactivity model experiment shows that the lung airway hyperreactivity of a CD23-deficient mouse can be reduced, the IL-17 level is reduced, and the inflammatory response is relieved.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

This invention relates to the application of cucurbitacin Q1 in the preparation of drugs for treating gliomas, belonging to the field of biomedical technology. The cucurbitacin Q1 of this invention has a significant inhibitory effect on glioma cell activity. It can inhibit the protein expression of JAK1, JAK2, and STAT4 by regulating the JAK-STAT signaling pathway, and block the phosphorylation activation of STAT3 protein, thus weakening downstream signal transduction in this pathway. Simultaneously, it can also exert an anti-tumor effect by regulating the phosphorylation level of related proteins in the PI3K-AKT signaling pathway. The cucurbitacin Q1 of this invention not only significantly inhibits the proliferation, invasion, and migration of glioma cells, but also significantly increases the apoptosis rate of glioma cells.

The application discloses a pea peptide mixture with calcium binding and osteogenesis promoting effects and application thereof, wherein the pea peptide mixture is derived from protein components in a by-product of pea starch extraction, is obtained through alkaline protease and papain enzymolysis and separation and purification, and is rich in aspartic acid and glutamic acid residues. The pea peptide mixture can effectively bind with calcium ions, the pea peptide mixture can promote calcium ion delivery in osteoblasts, improve alkaline phosphatase activity, and promote osteoblast differentiation, the osteogenesis promoting effect of the pea peptide mixture is related to epidermal growth factor receptor EGFR and downstream PI3K-Akt signal pathway regulation. The pea peptide mixture can improve glucocorticoid-induced zebrafish bone mass reduction, and up-regulate mRNA expression levels of ALP, EGFR, PI3K and Akt and other genes related to osteogenesis. The pea peptide mixture has both functions and nutrition, can be used for preparing products for promoting osteogenesis, improving bone mass, improving bone mass reduction and assisting in improving osteoporosis, and has a wide application prospect in the field of bone health.

The invention is suitable for the technical field of biological medicine, and provides application of 20 (S)-protopanaxatriol in preparation of a medicine for inhibiting tumor metastasis of liver cancer chemotherapy. According to the embodiment of the invention, a molecular mechanism of chemotherapy-induced liver cancer immunosuppression and metastasis increase is analyzed and studied, a key effect of an SHP2-PI3K / AKT signal axis in TAM M2 polarization is disclosed, a novel natural small molecule 20 (S)-protopanaxatriol capable of inhibiting the activity of SHP2 is provided, TAM is blocked from being polarized to an M2 type by inhibiting phosphorylation of SHP2 and activation of a downstream PI3K / AKT signal channel, and the activity of SHP2 is inhibited. Therefore, the tumor immune microenvironment after chemotherapy is improved, the tumor metastasis risk after chemotherapy is reduced, and the overall treatment effect is improved on the premise that safety is guaranteed.

This invention discloses the application of glycyrrhizin, an effective extract of licorice, in the preparation of drugs for the prevention, improvement, or treatment of hepatocellular carcinoma. This invention is the first to discover that glycyrrhizin possesses significant anti-hepatocellular carcinoma activity, significantly inhibiting the proliferation of human liver cancer cells HepG2 and Huh7, and inducing cell morphological shrinkage, decreased adhesion, and cell death. Transcriptome sequencing and network pharmacology combined analysis showed that glycyrrhizin exerts its effects by regulating the PI3K-Akt signaling pathway and cell cycle pathway, and regulates 10 core targets, including CCNA2, PLK1, AURKA, AKT1, EGFR, CASP3, BIRC7, HK1, PAEP, and ALDH3A1. Molecular docking confirmed the stable binding of glycyrrhizin to these targets. TCGA clinical database validation showed that the expression levels of these core targets were significantly correlated with the prognosis of hepatocellular carcinoma patients. This invention clarifies for the first time the pharmacodynamics and molecular mechanism of glycyrrhizin against hepatocellular carcinoma, providing a safe, efficient, multi-target natural small molecule anti-liver cancer candidate drug with significant clinical translational and application value.

This invention belongs to the field of biomedical technology, specifically relating to the application of a composition in the preparation of a drug for the prevention and treatment of polycystic ovary syndrome (PCOS). The composition comprises bovine spleen peptide and adenosine; the mass ratio of bovine spleen peptide to adenosine is 1:(1-2.5). Bovine spleen peptide, as a bioactive polypeptide, significantly improves insulin resistance associated with PCOS by targeting and activating the PI3K-Akt signaling pathway and promoting insulin receptor substrate phosphorylation. Adenosine, as a natural bioactive substance, significantly reduces serum luteinizing hormone and testosterone levels in rats and increases follicle-stimulating hormone levels, thereby effectively alleviating hyperandrogenism symptoms such as hirsutism and acne in PCOS. Furthermore, this composition can significantly improve polycystic pathological changes in the ovarian tissue of model rats, reduce the number of cystic dilated follicles, restore the granulosa cell layer structure, alleviate ovarian stromal hyperplasia, and promote normal follicular development.

The application belongs to the field of medicine and biotechnology, and particularly relates to an artificially circularized circular RNA and application thereof. The application provides an artificially circularized circular RNA, wherein the nucleotide sequence of the circular RNA is shown as SEQ ID NO. 1. The circular RNA (circmiR) can inhibit the function of miRNAs, improve the endogenous PTEN mRNA and PTEN protein levels, and enhance the sensitivity of LUAD to osimertinib. The results of examples show that the circmiR can improve the endogenous PTEN mRNA and PTEN protein levels, down-regulate the PI3K / AKT signaling pathway, and then significantly inhibit the proliferation, migration and invasion of LUAD cell lines, and can significantly enhance the sensitivity of the LUAD osimertinib-resistant cell line to osimertinib. The circular RNA based on the application can provide a new treatment mode for LUAD, and provide a new treatment strategy for LUAD osimertinib-resistant patients.

The invention belongs to the technical field of biological medicine and pharmacology, and particularly relates to EGCG-5-HT binary oxidation self-agglutination nanoparticles as well as a preparation method and application of the EGCG-5-HT binary oxidation self-agglutination nanoparticles. The EGCG (epigallocatechin gallate)-5-HT binary oxidation auto-agglutination nanoparticles disclosed by the invention are obtained by carrying out oxidation auto-agglutination on EGCG and 5-HT in an alkaline environment. The total concentration of the EGCG and the 5-HT in the reaction liquid is 1.0 to 3.0 mg / mL. The nanoparticles provided by the invention have an anti-oxidation effect, and can inhibit pyroptosis and regulate and control a cell cycle; an NF-kappa B signal channel is inhibited, and the anti-inflammatory effect is achieved; an MAPK signal channel is activated, and cell apoptosis is inhibited; a PI3K-Akt signal channel is activated, and cell proliferation and mucous membrane repair are promoted. When the compound is applied to preparation of IBD medicines, multi-mechanism synergistic treatment of anti-inflammatory, anti-oxidation and mucous membrane repair of IBD is realized; the invention also provides a preparation method of the nanoparticle, and the preparation method is mild in condition and simple.

The invention discloses a PI3K-AKT signal channel inhibitor. The PI3K-AKT signal channel inhibitor is prepared from the following components in percentage by mass: 49.0 percent to 49.45 percent of grape seed oil, 49.0 percent to 49.45 percent of pomegranate seed oil, 0.6 percent to 1.0 percent of 4-butylresorcinol and 0.5 percent to 1.0 percent of ascorbyl tetraisopalmitate. The invention also discloses a method for preparing the PI3K-AKT signal channel inhibitor as described above. The invention also discloses an application of the PI3K-AKT signaling pathway inhibitor in preparation of cosmetics for whitening, resisting aging or improving the skin state and a method for evaluating the efficacy of the cosmetics. According to the PI3K-AKT signal channel inhibitor provided by the invention, mRNA expression of PIK3CA and AKT1 genes in a PI3K-AKT signal channel can be effectively inhibited, and regulation and control on the signal channel are realized on a molecular level.

The application belongs to the technical field of biotechnology, and particularly relates to application of tobacco extracellular vesicles in Alzheimer's disease. It is found that the tobacco extracellular vesicles can significantly activate the PI3K-AKT signal pathway in primary astrocytes, improve the expression amount of P-PI3K protein and / or P-AKT protein in the PI3K-AKT signal pathway in astrocytes, promote degradation of A beta, improve learning and memory ability, reduce cognitive dysfunction, and thus prevent or treat Alzheimer's disease. The application provides a new idea for treatment of Alzheimer's disease.

A novel use of a drug for intervention in an IPMK target. It is found for the first time that HIF2α and GATA3 jointly regulate IPMK and a PI3K-AKT signaling pathway to mediate pathogenic Th2 cell differentiation, and it is verified for the first time that intervention in the IPMK target enables prevention and treatment of type II immune diseases and diseases caused by dysregulated Th2 / ILC2 differentiation and acts against tumors, aging and aging related diseases, thereby providing a new potential target for clinical treatment of type II immune diseases, tumors, diseases caused by dysregulated Th2 / ILC2 differentiation, and aging and aging related diseases, and achieving good prospects for application.

The invention belongs to the technical field of biological medicine, and provides application of a ZNF473-AKT axis as a target in diagnosis, treatment and prognosis evaluation of liver cancer in order to solve the limitation of an existing tumor diagnosis method in the aspects of sensitivity and specificity. The diagnostic reagent is a reagent for detecting whether ZNF473 is highly expressed or not. The ZNF473 is highly expressed, the phosphorylation level of AKT protein at the Ser473 site is activated, and proliferation and migration of tumor cells are promoted. After the ZNF473 is knocked down, the expression level of the phosphorylated AKT is reduced, and after the AKT agonist SC79 is added, the expression of the phosphorylated AKT is recovered. The results indicate that the ZNF473 can promote the proliferation and migration of tumor cells by regulating an AKT signal channel, and an experimental basis is provided for revealing the action mechanism of the ZNF473 in tumor generation and development.

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

The invention discloses application of melatonin in anti-inflammatory intervention of bilirubin encephalopathy, and the melatonin relieves neuroinflammation of the bilirubin encephalopathy by inhibiting activation of NLRP3 inflammasome, reducing GSDMD splitting decomposition and reducing the levels of proinflammatory factors TNF-alpha, IL-6 and IL-1beta and depending on a PI3K / AKT signal channel; the administration dosage of the melatonin is 10-20 mg / kg of body weight; the medicine is administrated through intraperitoneal injection; the melatonin plays an anti-inflammatory role by inhibiting the activation of NLRP3 inflammasome; the melatonin plays an anti-inflammatory role by reducing splitting decomposition of the GSDMD; the medicine further comprises a pharmaceutically acceptable carrier. The invention provides a new anti-inflammatory treatment strategy except for reducing bilirubin for the bilirubin encephalopathy.

The invention discloses an application of tripterine in preparation of a medicine for enhancing bladder cancer resisting activity of an MEK inhibitor, the Western blot experiment proves that the tripterine can effectively reduce p-STAT3 and p-Akt compensatory expression increase caused by the MEK inhibitor for the first time, so that STAT3 and Akt signal channel compensatory activation caused by the MEK inhibitor is reversed; in-vivo animal experiments show that the combination of the tripterine and the MEK inhibitor has a remarkable synergistic anti-tumor effect, and the anti-tumor effect of the tripterine is superior to that of any single drug; the pharmaceutical composition provided by the invention can effectively block the escape path of tumor cells by simultaneously inhibiting the three key signal paths of MEK / ERK, STAT3 and PI3K / Akt, overcomes or delays the drug resistance of the MEK inhibitor mediated by compensatory pathway activation, and provides a new drug combination strategy for the treatment of malignant tumors.

The invention relates to the technical field of biological medicine. The invention provides an application of sildenafil in preparation of a product for inhibiting adipogenic differentiation of mesenchymal stem cells. The use concentration of the sildenafil is 5-20 mg / L. The sildenafil with the concentration can remarkably inhibit the adipogenic differentiation effect of mesenchymal stem cells, and possibly inhibits the expression of adipogenic related genes by regulating a PI3K-AKT signal channel, so that bone marrow adipogenesis is reduced, the bone microstructure is improved, and osteoporosis and other diseases related to excessive adipogenic differentiation are improved. A new thought and application value are provided for reutilization of sildenafil in bone metabolism regulation and stem cell differentiation directions.

The application belongs to the technical field of biomedicine, and particularly relates to application of circRNA_0004468 in a drug for treating ischemic stroke. The application first discloses and verifies a competitive endogenous RNA (ceRNA) regulatory axis composed of circRNA_0004468, miR-1224 and VEGFA, which is a key molecular mechanism for RIPostC to play a neuroprotective role. Experiments prove that circRNA_0004468 can adsorb miR-1224 as a "molecular sponge", thereby relieving the inhibition of miR-1224 on VEGFA, up-regulating the expression of VEGFA, and then activating the PI3K / AKT signaling pathway and promoting angiogenesis, so as to finally reduce ischemia / reperfusion injury at the cell (OGD / R model) and animal (tMCAO model) levels.

The present application relates to a kind of Csi-Bantam inhibitor and its application in the preparation of the drug for treating liver fibrosis caused by Clonorchis sinensis infection, belong to biological manufacturing technical field, the present application has found that Csi-Bantam analog can be combined with the 3'-UTR region of Trim35 gene, by inhibiting the function of Csi-Bantam further blocks its PI3K / Akt signal pathway, can significantly inhibit the activation of hepatic stellate cell (activated hepatic stellate cell is the core driving cell of liver fibrosis, is also the main source of extracellular matrix) and the excessive secretion of type I, type III collagen fiber and other extracellular matrix, to effectively improve the process of liver fibrosis.The present application first discloses the new use of Csi-Bantam inhibitor in the preparation of liver fibrosis treatment drug.This discovery provides a new idea for the targeted treatment of liver fibrosis, and has important clinical transformation value for the treatment of liver fibrosis caused by parasitic infection and other factors.

The application relates to the field of drug crystal forms, in particular to a new crystal form of a compound of formula I and a preparation method thereof. The crystal form II of the compound of formula I has the comprehensive advantages of good physical and chemical stability, low moisture absorption, good solubility and bioavailability, and thus has certain drug property and drug development value. In addition, the preparation method of the crystal form II of the compound of formula I is simple in steps, mild in conditions, good in process repeatability, high in purity and low in cost, and is suitable for industrial large-scale production.

The present application relates to the technical field of biological diagnosis, and particularly relates to a mutant gene set for tumor molecular typing and application thereof, wherein the mutant gene set comprises 82 mutant genes including DNA methylation modification related genes, histone modification related genes, chromatin remodeling related genes, TCR signal pathway related genes, PI3K-AKT signal pathway related genes, JAK-STAT signal pathway related genes, immune escape related genes, P53 signal pathway related genes, tumor suppressor genes and NOTCH signal pathway related genes. The mutant gene set can be used for molecular typing, targeted therapy and overall survival prediction of intranodal peripheral T-cell lymphoma. The mutant gene set is verified by clinical trials, and is suitable for all primary and relapsed PTCL patients, relapsed or refractory peripheral T-cell lymphoma umbrella study based on genomics typing and PTCL patients receiving different treatment schemes, and has a very wide application range.

The invention discloses a novel application of a GRB2 gene, namely a preparation for enhancing tumor cell drug sensitivity is screened in order to inhibit the expression of the GRB2 gene. According to the application disclosed by the invention, the expression of the GRB2 gene in tumor cells is inhibited by virtue of an RNA interference technology, so that the phosphorylation level of key protein in a PI3K / Akt / mTOR signal channel can be remarkably reduced, the IC50 value of the tumor cells to chemotherapeutic drugs is reduced, and the apoptosis rate of the tumor cells is increased. Meanwhile, the relevance between GRB2 regulation and a PI3K / Akt signal channel is verified, when an Akt activator SC79 is used for reversing the inhibition effect of the signal channel, the drug sensitization effect mediated by GRB2 regulation is blocked, and it is proved that GRB2 affects the molecular mechanism of tumor cell drug sensitivity by regulating the PI3K / Akt / mTOR channel. The invention provides a new solution thought for the tumor chemotherapy drug resistance problem, and has important clinical transformation value.